左旋门冬酰胺酶联合方案治疗外周T细胞淋巴瘤疗效观察

摘要

目的:评价含左旋门冬酰胺酶(L-ASP)化疗方案治疗外周T细胞淋巴瘤(PTCL)的疗效.方法:初治T细胞淋巴瘤患者27例,L-ASP组15例接受联合化疗(LOD),对照组12例接受不含L-ASP的LOD.比较两组的有效率和2年生存率.结果:有效率(完全缓解加部分缓解)L-ASP组为73.3%,对照组为25%(P＜0.05).1年生存率L-ASP组57.4%,2年生存率43.1%,对照组1年生存率21.2%,2年生存率为0(P＜0.05).L-ASP治疗的不良反应主要表现为白细胞减少和胃肠道反应.结论:L-ASP为主的化疗方案可能提高PTCL的疗效和1年、2年生存率,不良反应可耐受.%Objective :To study the clinical efficacy of L- asparaginase (L- ASP) chemotherapy in the treatment of peripheral T cell lymphoma (PTCL). Methods: In this study, 27 cases of diagnosed T cell lymphoma patients were divided into two groups: L- ASP group( 15 cases) and CHOP group( 12 cases). The L- ASP group was treated with LOD chemotherapy containing L- ASP and the CHOP group was treated with combined chemotherapy without L - ASP. The effective rate and 2 - year' s survival rate were compared between the two groups. Results: The effective rate ( including complete and partial anesis) of L - ASP group was 73.3％, and the CHOP group was 25 ％ (P ＜ 0.05 ). The 1 - year' s survival rate and 2 - year' s survival rate of L - ASP group and CHOP group were 57.4％, 43.1％; 21.2％, 0％, respectively. The main side -effects of the LOD chemotherapy with L- ASP were mainly neutropenia and gastrointestinal reactions. Conclusion:L- ASP based chemotherapy may improve the efficacy of PTCL, increase 1 - year' s and 2 - year' s survival rate with tolerable side -effect.